Torsades de pointes
|Torsades de pointes|
|12-lead ECG of Torsades de Pointes (TdP) in a 56-year-old white female with low blood potassium (2.4 mmol/L) and low blood magnesium (1.6 mg/dL.)|
|Classification and external resources|
|Patient UK||Torsades de pointes|
Torsades de pointes or torsade depointes (TdP or simply torsade(s)) (French: [tɔʁsad də pwɛ̃t], translated as "twisting of the points"), is a specific type of abnormal heart rhythm that can lead to sudden cardiac death. It is a polymorphic ventricular tachycardia that exhibits distinct characteristics on the electrocardiogram (ECG). It was described by Dessertenne in 1966. Prolongation of the QT interval can increase a person's risk of developing this abnormal heart rhythm.
Action potential of cardiac muscles can be broken down into five phases:
- Phase 4: Exciting triggers (e.g. sinus node) will cause minor depolarization in the cells; this will result in increasing permeability of sodium channels, which trigger the opening of sodium channels.
- Phase 0: Sodium channels open, resulting in the entrance of Na+ into the cells; this results in the depolarization of the cardiac muscles.
- Phase 1: Sodium channels close; this stops depolarization. Potassium channels open, leading to an outward current of K+ out of the cells.
- Phase 2: Potassium channels remain open (outward current of K+), and calcium channels now also open (inward current of Ca++), resulting in a plateau state.
- Phase 3: Calcium channels close (inward Ca++ stops), but potassium channels are still open (outward K+ current); this persists until the cells gain back normal polarization (depolarization achieved). Please note that phase 0 lead to a net gain of Na+, while phases 1-3 lead to a net loss of K+. This imbalance is corrected by the Na+/K+-ATPase channel that pumps K+ into the cell and sodium out of the cell; this does not change polarization of the cells, but does restore ionic contents to its initial state.
Repolarization of the cardiomyocytes occurs in phases 1-3, and is caused predominantly by the outward movement of potassium ions. In Torsades de pointes, however, the repolarization is prolonged; this can be due to electrolyte disturbances (hypokalemia, hypomagnesemia, hypocalcemia), bradycardia, certain drugs (disopyramide, sotalol, amiodarone, amitriptyline, chlorpromazine, erythromycin) and/or congenital syndromes (LQT1-LQT4 gene defect).
The prolongation of repolarisation may result in subsequent activation of an inward depolarisation current, known as an early after-depolarisation, which may promote triggered activity. Re-entry, due to a dispersion of refractory periods, is also possible; this is because M Cells (found in the mid myocardial layer) show a more prolonged repolarization phase in response to potassium blockage than other cells. In turn, this produces a zone of functional refractoriness (inability to depolarize) in the mid myocardial layer. When new action potential is generated, the mid myocardial layer will remain in a refractory period, but the surrounding tissue will depolarize. As soon as the mid myocardial layer is no longer in a refractory period, excitation from nearby tissue will cause a retrograde current and a reentry circuit that will result in a positive chronotropic cycle, leading to tachycardia.
Signs and symptoms
Most episodes will revert spontaneously to a normal sinus rhythm. If this does not occur, however, possible adverse outcomes include palpitations, dizziness, lightheadedness (during shorter episodes), fainting (during longer episodes), and sudden cardiac death.
Common causes for torsades de pointes include diarrhea, low blood magnesium, and low blood potassium. It is commonly seen in malnourished individuals and chronic alcoholics, since they are often deficient in potassium and/or magnesium. Certain combinations of drugs resulting in drug interactions can contribute to torsades de pointes risk. QT prolonging medications such as clarithromycin, levofloxacin, or haloperidol, when taken concurrently with a specific cytochrome P450 inhibitor, such as fluoxetine, cimetidine, or certain foods like grapefruit, can result in higher-than-normal levels of QT prolonging medications in the bloodstream and therefore increase a person's risk of developing torsades de pointes. In addition, inherited long QT syndrome significantly increases the risk of episodes of TdP.
Knowledge that TdP may occur in patients taking certain prescription drugs has been both a major liability and reason for retirement of these medications from the marketplace. Examples of compounds linked to clinical observations of TdP include amiodarone, fluoroquinolones, methadone, lithium, chloroquine, erythromycin, amphetamine, ephedrine, pseudoephedrine, methylphenidate, and phenothiazines. It has also been shown as a side effect of certain anti-arrhythmic medications, such as sotalol, procainamide, and quinidine. The gastrokinetic drug cisapride (Propulsid) was withdrawn from the US market in 2000 after it was linked to deaths caused by long QT syndrome-induced torsades de pointes. In many cases, this effect can be directly linked to QT prolongation mediated predominantly by inhibition of the hERG channel.
In September 2011 (subsequently updated in March 2012 and February 2013), the FDA issued a warning concerning increased incidence of QT prolongation in patients prescribed doses of the antidepressant Celexa (citalopram) above 40 mg per day, considered the maximum allowable dosage, thereby increasing the risk of Torsades. However, a study, "Evaluation of the FDA Warning Against Prescribing Citalopram at Doses Exceeding 40 mg," reported no increased risk of abnormal arrhythmias, thus questioning the validity of the FDA's warning.
The following is a list of factors associated with an increased tendency towards developing torsades de pointes:[medical citation needed]
- Hypokalemia (low blood potassium)
- Hypomagnesemia (low blood magnesium)
- Hypocalcemia (low blood calcium)
- Bradycardia (slow heartbeat)
- Heart failure
- Left ventricular hypertrophy
- Subarachnoid hemorrhage
The ECG tracing in torsades demonstrates a polymorphic ventricular tachycardia with a characteristic illusion of a twisting of the QRS complex around the isoelectric baseline (peaks, which are at first pointing up, appear to be pointing down for subsequent "beats" when looking at ECG traces of the "heartbeat"). It is hemodynamically unstable and causes a sudden drop in arterial blood pressure, leading to dizziness and fainting. Depending on their cause, most individual episodes of torsades de pointes revert to normal sinus rhythm within a few seconds; however, episodes may also persist and possibly degenerate into ventricular fibrillation, leading to sudden death in the absence of prompt medical intervention. Torsades de pointes is associated with long QT syndrome, a condition whereby prolonged QT intervals are visible on an ECG. Long QT intervals predispose the patient to an R-on-T phenomenon, wherein the R-wave, representing ventricular depolarization, occurs during the relative refractory period at the end of repolarization (represented by the latter half of the T-wave). An R-on-T can initiate torsades. Sometimes, pathologic T-U waves may be seen in the ECG before the initiation of torsades.
A "short-coupled variant of torsade de pointes", which presents without long QT syndrome, was also described in 1994 as having the following characteristics:
- Drastic rotation of the heart's electrical axis
- Prolonged QT interval (LQTS) - may not be present in the short-coupled variant of torsade de pointes
- Preceded by long and short RR-intervals - not present in the short-coupled variant of torsade de pointes
- Triggered by a premature ventricular contraction (R-on-T PVC)
The phenomenon was originally described in a French medical journal by Dessertenne in 1966, when he observed this cardiac rhythm disorder in an 80-year-old female patient with complete intermittent atrioventricular block. In coining the term, he referred his colleagues to the "Dictionnaire Le Robert," a bilingual French English dictionary, of which his wife had just given him a copy. Here, "torsade" is defined as:
- a bundle of threads, twisted in a helix or spiral, for ornamental purposes (such as in an Aran sweater)
- long hair twisted together
- an ornamental motif, as seen on architectural columns
The singular and plural forms (torsade de pointes and torsades de pointes) have both often been used. The question of whether either one is grammatically "correct" and the other "incorrect" has repeatedly arisen. This is seen among major medical dictionaries, where one enters only the plural form, another enters the plural form as the headword but lists the singular as a variant, and yet another enters the singular form as the headword and gives a usage comment saying that the plural is not preferred. One group of physicians has suggested that it would make the most sense to use the singular form to refer to the arrythmia entity (where an arrythmia may involve one or multiple episodes), and that one might best reserve the plural form for describing repeated twistings during a single episode. Regarding the natural language variation, they concluded, in good nature, "Wasn't it the French who coined the term 'vive la difference?'"
- Dessertenne, F. (1966). "La tachycardie ventriculaire a deux foyers opposes variables". Archives des maladies du coeur et des vaisseaux (in French). 59 (2): 263–272. ISSN 0003-9683. PMID 4956181. Prepaired by Rahel farhad
- Davidson, Sir Stanley (2010). Colledge, Walker, Ralston, ed. Davidson's Principles and Practice of Medicine, 21st Edition. United Kingdom: Elsevier. p. 568. ISBN 978-0-7020-3084-0.
- Yap, Yee Guan; Camm, A John (2017-01-17). "Drug induced QT prolongation and torsades de pointes". Heart. 89 (11): 1363–1372. ISSN 1355-6037. PMC . PMID 14594906.
- Napolitano, C.; Priori, S. G.; Schwartz, P. J. (1994-01-01). "Torsade de pointes. Mechanisms and management". Drugs. 47 (1): 51–65. ISSN 0012-6667. PMID 7510621. doi:10.2165/00003495-199447010-00004.
- Labant, MaryAnn (November 15, 2014). "Weaving a Stronger Drug Safety Net". Gen. Eng. Biotechnol. News (paper). 34 (20). p. 1.
- "Drugs That Prolong the QT Interval or Induce Torsades de Pointes". Point of Care Quick Reference. American Academy of Pediatrics. March 11, 2010. Archived from the original on March 7, 2014.
- "FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses" (Press release). USFDA. February 15, 2013. Retrieved December 13, 2014.
- Deshmukh, Anand; Ulveling, Kyle; et al. (2012). "Prolonged QTc interval and torsades de pointes induced by citalopram". Tex. Heart Inst. J. 39 (1): 68–70. PMC . PMID 22412232.
- K Zivin; PN Pfeiffer; ASB Bohnert; D Ganoczy; FC Blow; BK Nallamothu; HC Kales (June 1, 2013). "Evaluation of the FDA Warning Against Prescribing Citalopram at Doses Exceeding 40 mg". Am J Psychiatry. 170 (6): 642–650. PMID 23640689. doi:10.1176/appi.ajp.2013.12030408.
- John, J.; Amley, X.; Bombino, G.; Gitelis, C.; Topi, B.; Hollander, G.; Ghosh, J. (2010). "Torsade de Pointes due to Methadone Use in a Patient with HIV and Hepatitis C Coinfection". Cardiology Research and Practice. 2010: 1–4. PMC . PMID 21253542. doi:10.4061/2010/524764.
- Leenhardt A, Glaser E, Burguera M, Nürnberg M, Maison-Blanche P, Coumel P (January 1994). "Short-coupled variant of torsade de pointes. A new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias" (PDF). Circulation. 89 (1): 206–15. PMID 8281648. doi:10.1161/01.CIR.89.1.206.
- Hoshino, Kenji; Ogawa Kiyoshi; et al. (October 2004). "Optimal administration dosage of magnesium sulfate for torsades de pointes in children with long QT syndrome". J. Am. Coll. Nutr. 23 (5): 497S–500S. PMID 15466950. doi:10.1080/07315724.2004.10719388.
- Hoshino, Kenji; Ogawa, Kiyoshi; et al. (April 2006). "Successful uses of magnesium sulfate for torsades de pointes in children with long QT syndrome". Pediatr. Int. 48 (2): 112–7. PMID 16635167. doi:10.1111/j.1442-200X.2006.02177.x.
- Moise NS (1999), "As Americans, we should get this right [correspondence and response]", Circulation, 100: 1462, doi:10.1161/01.CIR.100.13.1462.